|5.||Critical Illness (Critically Ill)
|1.||Walsh, Thomas J: 19 articles (12/2015 - 12/2002)|
|2.||Benjamin, Daniel K: 13 articles (07/2015 - 08/2006)|
|3.||Pontón, José: 11 articles (03/2010 - 03/2004)|
|4.||Ostrosky-Zeichner, Luis: 10 articles (05/2014 - 12/2003)|
|5.||Reboli, Annette C: 10 articles (01/2014 - 02/2007)|
|6.||Perfect, John R: 10 articles (01/2012 - 05/2003)|
|7.||Quindós, Guillermo: 9 articles (01/2015 - 02/2004)|
|8.||Pappas, Peter G: 9 articles (05/2014 - 06/2007)|
|9.||Clancy, Cornelius J: 8 articles (01/2016 - 05/2006)|
|10.||Kartsonis, Nicholas A: 8 articles (06/2015 - 08/2003)|
|1.||caspofungin (Cancidas)FDA Link
07/01/2011 - "We hypothesized that higher doses of caspofungin would be effective against invasive candidiasis caused by the more virulent species Candida albicans, including isolates resistant to this echinocandin. "
07/01/2011 - "These data suggest that caspofungin dose escalation for invasive candidiasis may not be consistently effective against resistant C. "
01/01/2007 - "Caspofungin is a new antifungal agent effective in the treatment of invasive candidiasis. "
08/01/2007 - "Caspofungin has demonstrated efficacy in invasive candidiasis. "
08/01/2010 - "A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients."
|2.||Fluconazole (Zonal)FDA LinkGeneric
08/01/2011 - "Fluconazole prophylaxis is effective in preventing invasive candidiasis in extremely low-birthweight (ELBW) infants. "
12/01/2014 - "Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants. "
03/01/2011 - "Fluconazole is used extensively in human medicine to treat mucosal and invasive candidiasis and has been used in birds; however, there have been few pharmacokinetic studies in avian species to guide safe and effective treatment. "
11/01/1996 - "Because of its pharmacokinetic properties, fluconazole can be specially useful in the treatment of invasive candidiasis. "
01/01/1998 - "The isolates were examined in a murine model of invasive candidiasis and were ranked by their relative response to fluconazole by using both improvement in survival and reduction in fungal burden in the kidney. "
10/01/2007 - "The echinocandins have potent fungicidal activity against most Candida species, but there are few data comparing the safety and efficacy of echinocandins in the treatment of invasive candidiasis. "
07/01/2014 - "Echinocandins are employed as the first-line treatment for invasive candidiasis until the fungal species is determined and confirmed by clinical diagnosis. "
01/01/2014 - "Echinocandins are indicated as first-line treatment for invasive candidiasis in moderate to severe illness. "
08/01/2008 - "The echinocandins as a class offer an advance in the treatment of invasive candidiasis, an additional option for prophylaxis and an attractive choice for the study of combination antifungal therapy. "
12/01/2015 - "The current standard of treatment of invasive candidiasis with echinocandins requires once-daily therapy. "
06/01/2004 - "The clearance of anidulafungin was influenced by weight and gender, and subjects in the invasive candidiasis study had a typical clearance that was approximately 30% higher than subjects from other studies. "
01/01/2003 - "In January 2003, Versicor announced that positive results from a phase II trial for anidulafungin IV treatment involving 120 patients in the US with invasive candidiasis/candidaemia, have led to another double-blind, randomised phase III trial being conducted in the US, Canada and Europe for this indication. "
06/01/2013 - "In addition, we demonstrated anidulafungin efficacy in treating biofilm-related invasive candidiasis."
10/01/2011 - "Anidulafungin was mostly used for pre-emptive (69%) and first-line treatment (17%) of invasive candidiasis. "
01/01/2014 - "An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America."
|5.||micafungin (FK463)FDA Link
03/31/2009 - "Micafungin is safe and effective in the treatment of children and adults with invasive candidiasis. "
02/01/2014 - "Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species."
01/01/2014 - "A multicenter observational study was conducted in Italy to assess the safety of micafungin in the daily clinical practice for the treatment of proven and suspected invasive candidiasis (IC), as well as to describe rates of clinical response to micafungin treatment. "
01/01/2014 - "Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study."
03/31/2009 - "Althought the European Medicines Agency approved in 2008 the use of Micafungin for the treatment of invasive candidiasis in children, the available clinical experience is limited and currently more clinical studies are warranted to define its efficacy and safety in neonates."
|6.||Amphotericin B (Amphotericin)FDA LinkGeneric
04/01/1989 - "We have reviewed 38 patients with invasive candidiasis and examined its predisposing factors, usefulness and limitation of cultural study in its diagnosis, and effective usage of amphotericin B in its treatment. "
04/01/1989 - "[Invasive candidiasis: its predisposing factors, usefulness and limitation of cultural study in its diagnosis, and consideration on the appropriate amphotericin B therapy]."
10/15/2012 - "The objective of this work was to assess the antifungal activity of a tropically stable formulation of amphotericin B (AmB) (iCo-010) over short period of treatment in a rat model of invasive candidiasis. "
10/15/2012 - "Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis."
07/01/2003 - "Antibody to HSP90 is closely associated with recovery in patients with invasive candidiasis who are receiving amphotericin B (AMB). "
01/01/2011 - "Prediction of the clinical outcome in invasive candidiasis patients based on molecular fingerprints of five anti-Candida antibodies in serum."
03/01/2010 - "The need for new options for the treatment of invasive candidiasis has fuelled the use of antibodies in combination with conventional antifungal therapy. "
12/01/2006 - "The usefulness to diagnose and monitor invasive candidiasis (IC) using beta-glucan (BG) and antibodies against Candida albicans germ tubes (CAGT) was evaluated in a twice-weekly screening of 35 episodes in neutropenic adults at high risk. "
09/01/2005 - "Syscan3, a kit for detection of anti-Candida antibodies for diagnosis of invasive candidiasis."
10/01/2002 - "Our observations may also help explain why subjects with elevated anti-Candida antibody titers, inclusive of anti-MP and anti-GG antibodies, remain nonetheless susceptible to invasive candidiasis."
|8.||voriconazole (Vfend)FDA LinkGeneric
12/01/2010 - "Economic data to guide the use of voriconazole as prophylaxis or empirical therapy as well as targeted therapy against invasive candidiasis remain limited."
11/01/2003 - "Voriconazole salvage treatment of invasive candidiasis."
11/01/2003 - "Voriconazole has promise as a salvage agent for the treatment of invasive candidiasis, even in the settings of previous azole therapy and infection due to Candida krusei."
12/01/2003 - "Voriconazole is active in oropharyngeal and esophageal candidiasis, in refractory invasive candidiasis and as a first line treatment of invasive aspergillosis with better results than amphotéricine B. "
01/01/2009 - "Voriconazole is a synthetic, broad spectrum triazole antifungal agent, with FDA-approved indications for the treatment of invasive aspergillosis, esophageal candidiasis, candidemia in nonneutropenic patients, invasive candidiasis, and infections due to Scedosporium apiospermum and Fusarium species in patients refractory to or intolerant of other therapy. "
|9.||liposomal amphotericin BFDA Link
02/17/2004 - "It is now the subject of a multinational, double-blind, placebo-controlled trial, in patients with culture-confirmed invasive candidiasis on liposomal amphotericin B."
01/01/2015 - "Herein, we report two preterms with invasive candidiasis refractory to liposomal amphotericin B (AMB) treatment in spite of low MIC levels (MIC: 0.5 mcg/mL). "
12/01/2008 - "MCFG, FLCZ and AMPH-B are recommended as first line drugs for invasive candidiasis, and L-AMB, VRCZ, ITCZ are considered as alternative drugs in Japanese guideline."
12/01/2005 - "The pharmacokinetics of amphotericin B lipid complex (ABLC) were investigated in neonates with invasive candidiasis enrolled in a phase II multicenter trial. "
03/01/2001 - "Amphotericin B lipid complex for neonatal invasive candidiasis."
05/01/2015 - "We reviewed the medical literature and extracted information on clinical and observational studies evaluating the use of antifungal agents in neonates with invasive candidiasis. "
01/01/2014 - "The aim of the study was to determine the prevalence of yeast-like fungi in invasive candidiasis and to estimate its susceptibility to chosen antifungal agents. "
02/01/2011 - "The aim of our study was to analyze the spectrum and characteristic of invasive candidiasis in selected haematological departments in the Czech and Slovak Republics, and to compare minimum inhibitory concentrations (MIC) of some antifungal agents for isolates obtained. "
01/01/2014 - "Early diagnosis of invasive candidiasis is critical in order to initiate antifungal agents promptly. "
12/01/2013 - "Despite substantial advances in antifungal agents and treatment strategies, invasive candidiasis remains associated with a high mortality. "
|1.||Intensive Care (Surgical Intensive Care)
01/01/2015 - "Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study."
12/01/2013 - "Invasive candidiasis in pediatric intensive care in Greece: a nationwide study."
04/01/2007 - "The study presented here was performed in order to create a rule that identifies subjects at high risk for invasive candidiasis in the intensive care setting. "
04/01/2015 - "Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol."
01/01/2011 - "Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting."
09/01/2014 - "Although there has been an improved management of Invasive Candidiasis in the last decade, still controversial issues remain, especially in different therapeutic critical care scenarios. "
07/01/2014 - "Although there has been an improved management of invasive candidiasis in the last decade, still controversial issues remain, especially in different therapeutic critical care scenarios. "
09/01/2010 - "Current diagnostic approaches to invasive candidiasis in critical care settings."
11/04/2014 - "Invasive candidiasis in critical care setting, updated recommendations from "Invasive Fungal Infections-Clinical Forum", Iran."
11/01/2005 - "To compare the management of invasive candidiasis between infectious disease and critical care specialists. "
04/01/2012 - "Caspofungin, a novel echinocandin compound, has been approved for the treatment of esophageal and suspected invasive candidiasis and as salvage therapy for invasive aspergillosis. "
05/01/2003 - "Caspofungin is a promising agent as first-line therapy for invasive candidiasis, and as salvage therapy for invasive aspergillosis. "
04/01/2007 - "Caspofungin has demonstrated efficacy in experimental models of invasive candidiasis and aspergillosis, which reflect its activity in the treatment of oropharyngeal, esophageal and disseminated candidiasis, as well as salvage therapy for patients with invasive aspergillosis."
03/01/2011 - "Caspofungin, the first licensed echinocandin, is a novel class of antifungal and is approved for use in children 3 months of age or older for the treatment of invasive candidiasis, salvage therapy for invasive aspergillosis and as empirical therapy for febrile neutropenia. "
01/01/2010 - "Micafungin and caspofungin are recommended as primary or alternative treatment of candidemia and esophageal or invasive candidiasis, and as salvage therapy for invasive aspergillosis. "
05/01/2011 - "parapsilosis; the latter causing invasive candidiasis mainly associated with central venous catheter management, especially in neonatal units. "
12/01/2005 - "Candida albicans biofilms form on indwelling medical devices (e.g., denture acrylic or intravenous catheters) and are associated with both oral and invasive candidiasis. "
12/01/2005 - "Predisposing factors were similar to those of invasive candidiasis, with intravascular catheter and antibiotic therapy being the most frequent. "
10/01/2010 - "Previous antibiotics, presence of a central catheter or endotracheal tube, and center were strongly associated with invasive candidiasis. "
09/01/2007 - "Most patients had well-recognized risk factors for invasive candidiasis, including broad-spectrum antibiotics, central venous catheters, and hyperalimentation. "